- Home
- GWH vs MCRB Comparison
GWH vs MCRB Comparison
Compare GWH & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- MCRB
- Stock Information
- Founded
- GWH 2011
- MCRB 2010
- Country
- GWH United States
- MCRB United States
- Employees
- GWH N/A
- MCRB N/A
- Industry
- GWH Industrial Machinery/Components
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- GWH Miscellaneous
- MCRB Health Care
- Exchange
- GWH Nasdaq
- MCRB Nasdaq
- Market Cap
- GWH 117.9M
- MCRB 142.0M
- IPO Year
- GWH N/A
- MCRB 2015
- Fundamental
- Price
- GWH $5.80
- MCRB $0.95
- Analyst Decision
- GWH Buy
- MCRB Buy
- Analyst Count
- GWH 5
- MCRB 4
- Target Price
- GWH $1.14
- MCRB $4.17
- AVG Volume (30 Days)
- GWH 108.9K
- MCRB 3.0M
- Earning Date
- GWH 11-05-2024
- MCRB 10-31-2024
- Dividend Yield
- GWH N/A
- MCRB N/A
- EPS Growth
- GWH N/A
- MCRB N/A
- EPS
- GWH N/A
- MCRB N/A
- Revenue
- GWH $7,427,000.00
- MCRB $374,000.00
- Revenue This Year
- GWH $4,045.09
- MCRB N/A
- Revenue Next Year
- GWH N/A
- MCRB N/A
- P/E Ratio
- GWH N/A
- MCRB N/A
- Revenue Growth
- GWH 117.99
- MCRB N/A
- 52 Week Low
- GWH $5.60
- MCRB $0.54
- 52 Week High
- GWH $31.65
- MCRB $3.28
- Technical
- Relative Strength Index (RSI)
- GWH 29.97
- MCRB 53.10
- Support Level
- GWH $5.71
- MCRB $0.77
- Resistance Level
- GWH $7.76
- MCRB $0.87
- Average True Range (ATR)
- GWH 0.80
- MCRB 0.10
- MACD
- GWH -0.14
- MCRB 0.01
- Stochastic Oscillator
- GWH 6.71
- MCRB 33.44
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.